E.Merge Technology Acquisition Corp. Announces Liquidation For ~$10.06/Share

E.Merge Technology Acquisition Corp. (NASDAQ:ETAC) (the "Company") announced today that, due to its inability to consummate an initial business combination within the time period required by its Second Amended

E.Merge Technology Acquisition Corp. (NASDAQ:ETAC) (the “Company”) announced today that, due to its inability to consummate an initial business combination within the time period required by its Second Amended and Restated Certificate of Incorporation, as amended (the “Amended Charter”), the Company intends to dissolve and liquidate in accordance with the provisions of its Amended Charter, effective as of the close of business on September 4, 2022, and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering (the “Public Shares”), at a per-share redemption price of approximately $10.06.

Total
0
Shares
Related Posts
Read More

Immuron Announced in a Publication from the Hebrew University Hadassah Medical Center ‘Augmented Antiviral T Cell Immunity by Oral Administration of Imm-124e in Preclinical Models and a Phase I/iia Clinical Trial: a Method for the Prevention and Treatm…

Immuron Limited (NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, is pleased to notify shareholders of a recent publication describing the potential antiviral benefits of IMM-124E in a mouse model

IMRN